Here's a concise summary of the investor presentation: **Business Performance:** Anuh Pharma had a strong Q1 FY27. Revenue grew 3.93% YoY to 193.81 Cr, but Net Profit (PAT) surged 37.63% YoY to 11.42 Cr.

EBITDA jumped 41.56% to 19.36 Cr, significantly boosting margins.

This robust performance stemmed from a richer product mix, tight cost control, and efficient asset utilization.

Production volume also rose 19.46% YoY. **Growth Drivers or Strategy:** High-value products in regulated markets are now their core growth engine.

Strategy focuses on volume expansions, process innovation, cost optimization, and diversifying exports.

Anuh Pharma targets a steady 15-20% annual growth. **Recent Developments:** Key regulatory wins: Anuh Pharma secured crucial USFDA and EU GMP clearances, vital for market access.

They passed a USFDA inspection with zero observations and received WHO pre-qualification for Amodiaquine HCL. **Key Financial Metrics:** Q1 FY27 highlights: Revenue 193.81 Cr (+3.93% YoY), PAT 11.42 Cr (+37.63% YoY), and EPS 1.14 Rs (+37.63% YoY). **Management Commentary / Outlook:** Management expressed confidence, attributing profit gains to a strategic shift towards higher-value regulated market products.

They expect strengthening returns without added debt, actively developing new APIs.